Influx Healthtech Ltd
INFLUXInflux Healthtech Ltd's price has outrun its earnings. +91.0% in a year against EPS +20.4% — the market is paying now for delivery later.
The sharpest disagreement: profits are rising, but only 44% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (56 weeks in) while the P/E sits at the 97th percentile of its own 1-year range. Underneath, the last four quarters read improving — profit +37.5% year on year, and 44% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Influx Healthtech Ltd trades at ₹296, in a confirmed uptrend and 56 weeks into that stage. That is +26.3% against its own 200-day average. It sits at 96% of a 52-week range of ₹169 to ₹301. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 5 straight weeks.
Today the stock is in a confirmed uptrend — week 56 of stage 2, confirmed. At ₹296 it trades +26.3% versus its 200-day average and sits at 96% of its 52-week range (₹169–₹301).
Against the market, two honest reads. Cumulative: over the last 1.1 years the stock moved +120% while the NIFTY 500 moved +0% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 5 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Influx Healthtech Ltd trades at 33.4× P/E, at the pricey end of its own range (97th percentile). Its long-run median P/E is 25.8×, measured across 1.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 33.4× is at the pricey end of its own range (97th percentile), against a long-run median of 25.8× measured over 1.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved +20.4% against a +91.0% price move — the price outran earnings, pushing the multiple UP its own range.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Influx Healthtech Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 4 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +40.0% | +24.6% | — | — |
| Profit | +61.5% | +44.2% | — | — |
| EPS | +20.4% | −85.5% | — | — |
| Share price | +91.0% | — | — | — |
4-Factor Sector Score
65.1/100 — rank 40 of 43 in Pharma - Formulators · 50% evidence confidence · provisional, ranked below fully-evidenced peers
Influx Healthtech Ltd scores 65.1 out of 100 against the 43 companies it is compared with in Pharma - Formulators, ranking 40. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 19.1 + 20.3 + 10 + 15.7 = 65.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Influx Healthtech Ltd reported ₹80.0 Cr of revenue in the Mar 26 quarter, +40.4% year on year. That is the 2nd straight quarter of year-on-year growth. The last full year, FY26, came in at ₹147 Cr. The last four reported quarters add to ₹252 Cr.
FY26 revenue came in at ₹147 Cr (+40.0% on the year). The latest quarter (Mar 26) printed ₹80.0 Cr, +40.4% year on year — the 2nd consecutive quarter of year-over-year growth.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Influx Healthtech Ltd's operating margin is 19.0% in the Mar 26 quarter, −1.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged 11.0% to 20.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 19.0%, −1.0 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 11.0%–20.0%, and FY26's 20.0% is the top of that band — a record year.
Why: the numbers show the operating margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Influx Healthtech Ltd earned ₹11.0 Cr of net profit in the Mar 26 quarter, +37.5% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹21.0 Cr. That is 13.8% of the quarter's revenue.
Mar 26 profit was ₹11.0 Cr, +37.5% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹21.0 Cr (+61.5%).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 44% of Influx Healthtech Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹4.0 Cr of operating cash against ₹21.0 Cr of profit. After ₹16.0 Cr of capital spending, ₹−12.0 Cr was left as free cash.
FY26: operating cash of ₹4.0 Cr against reported profit of ₹21.0 Cr, leaving free cash of ₹−12.0 Cr after ₹16.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 44% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 44%: the cash cycle stretched 81 days between FY22 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 81 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Influx Healthtech Ltd's cash conversion cycle runs 71 days in FY26, up from −10 days in FY22. Capital spending ran ₹34.0 Cr over the last 3 years. At FY26 sales of ₹147 Cr each day of that cycle holds about ₹0.4 Cr, so roughly ₹29.0 Cr sits inside the business at any moment.
FY26: debtors at 84 days, inventory at 67 days — roughly 2.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 71 days, looser than FY22's −10.
The full loop: cash goes out to suppliers and production on day 0; stock waits 67 days to sell; customers pay about 84 days after that; and suppliers themselves are paid at 80 days — netting out to the 71-day cycle.
In money terms: at FY26 sales of ₹147 Cr, each day of the cycle holds about ₹0.4 Cr — so the 71-day loop keeps roughly ₹29.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹34.0 Cr over the last 3 fiscal years against ₹9.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹3.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Influx Healthtech Ltd earns a ROCE of 40% in FY26. Return on invested capital clears the cost of that capital by +16.2 percentage points, so growth here adds value rather than only size. The wiring behind it is 14.3% net margin on 1.19× asset turns.
FY26 ROCE is 40%.
Why the return is what it is — the wiring (FY26): 14.3% net margin × 1.19× asset turns × 1.23× balance-sheet leverage ≈ 20.9% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 28.2% − 12.0% = a +16.2 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Influx Healthtech Ltd carries ₹0.0 Cr of borrowings against ₹101 Cr of equity in FY26, a debt-to-equity of 0.00. Over 5 years borrowings went from ₹0.0 Cr to ₹0.0 Cr. Capital spending ran ₹34.0 Cr across the last 3 of those years.
FY26: borrowings of ₹0.0 Cr against equity of ₹101 Cr — a debt-to-equity of 0.00. Over 5 years borrowings went from ₹0.0 Cr to ₹0.0 Cr while capital spending ran ₹34.0 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Influx Healthtech Ltd moved a full percentage point over the last two years — the register is quiet. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — .
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Influx Healthtech Ltd: the Z-score reads 15.04. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 15.04 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 15.04.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Lupin LtdLUPIN | 74.1/100Favorable setup89% evidence | TURNING | 29.7/35 Revenue 23.1% · PAT 62% · OPM change 10 pp 88% evidence | 21.0/25 ROCE 29.9% · OPM 33% 100% evidence | 16.3/20 P/E 19.4× · PEG 0.54 65% evidence | 7.1/20 RS sector -7.4% · RS bench 9% · 1Y 23.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 29.7 + 21 + 16.3 + 7.1 = 74.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Kwality Pharmaceuticals Ltd539997 | 72.8/100Favorable setup78% evidence | LEADER | 29.0/35 Revenue 35.7% · PAT 71.8% · OPM change 3 pp 83% evidence | 17.8/25 ROCE 24.2% · OPM 25% 76% evidence | 6.4/20 P/E 39.4× · PEG — 50% evidence | 19.6/20 RS sector 51.5% · RS bench 73.2% · 1Y 121.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 29 + 17.8 + 6.4 + 19.6 = 72.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3Caplin Point Laboratories LtdCAPLIPOINT | 68.3/100Favorable setup96% evidence | LEADER | 19.6/35 Revenue 12.9% · PAT 20.1% · OPM change 1 pp 88% evidence | 18.9/25 ROCE 24.6% · OPM 34% 100% evidence | 12.1/20 P/E 29.8× · PEG 0.99 100% evidence | 17.7/20 RS sector 5.7% · RS bench 24.1% · 1Y 23.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.6 + 18.9 + 12.1 + 17.7 = 68.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Bliss GVS Pharma LtdBLISSGVS | 66.9/100Favorable setup78% evidence | LEADER | 27.2/35 Revenue 14.3% · PAT 48.4% · OPM change 6 pp 83% evidence | 13.2/25 ROCE 16.9% · OPM 17% 76% evidence | 6.9/20 P/E 37.5× · PEG — 50% evidence | 19.6/20 RS sector 64.6% · RS bench 87.2% · 1Y 203.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 27.2 + 13.2 + 6.9 + 19.6 = 66.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Glenmark Pharmaceuticals LtdGLENMARK | 65.8/100Favorable setup100% evidence | ASLEEP | 30.5/35 Revenue 32.9% · PAT 100% · OPM change 2 pp 100% evidence | 17.5/25 ROCE 39.8% · OPM 20% 100% evidence | 12.2/20 P/E 20.2× · PEG 1.43 100% evidence | 5.6/20 RS sector -10.3% · RS bench 5.6% · 1Y 4.1%3 of 12 weeks ahead 100% evidence |
| Exact sum: 30.5 + 17.5 + 12.2 + 5.6 = 65.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -10.3% and the one-year return is 4.1%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 6Emcure Pharmaceuticals LtdEMCURE | 65.4/100Favorable setup71% evidence | LEADER | 24.6/35 Revenue 16.6% · PAT 32.9% · OPM change 0 pp 83% evidence | 17.9/25 ROCE 24% · OPM 19% 76% evidence | 9.4/20 P/E 39.3× · PEG — 15% evidence | 13.5/20 RS sector 7.1% · RS bench 25.6% · 1Y 39.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.6 + 17.9 + 9.4 + 13.5 = 65.4 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 7Corona Remedies LtdCORONA | 64.5/100Mixed-positive evidence73% evidence | BREAKING OUT | 23.7/35 Revenue 18% · PAT 19.3% · OPM change 2 pp 100% evidence | 19.4/25 ROCE 33.3% · OPM 22% 100% evidence | 11.4/20 P/E 60.5× · PEG 1.18 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —9 of 12 weeks ahead 0% evidence |
| Exact sum: 23.7 + 19.4 + 11.4 + 10 = 64.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Ajanta Pharma LtdAJANTPHARM | 61.4/100Mixed-positive evidence100% evidence | BREAKING OUT | 21.9/35 Revenue 20.2% · PAT 22.2% · OPM change -1 pp 100% evidence | 18.9/25 ROCE 34.5% · OPM 26% 100% evidence | 5.7/20 P/E 38.2× · PEG 2.31 100% evidence | 14.9/20 RS sector 3.1% · RS bench 21% · 1Y 24.5%7 of 12 weeks ahead 100% evidence |
| Exact sum: 21.9 + 18.9 + 5.7 + 14.9 = 61.4 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 9Zydus Lifesciences LtdZYDUSLIFE | 61.2/100Mixed-positive evidence96% evidence | LEADER | 17.1/35 Revenue 16.8% · PAT 9.7% · OPM change 1 pp 88% evidence | 17.8/25 ROCE 21.1% · OPM 34% 100% evidence | 13.9/20 P/E 20.7× · PEG 1.4 100% evidence | 12.4/20 RS sector -3.3% · RS bench 13.8% · 1Y 15.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 17.8 + 13.9 + 12.4 = 61.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Rubicon Research LtdRUBICON | 60.9/100Mixed-positive evidence69% evidence | BREAKING OUT | 23.9/35 Revenue 36.6% · PAT 84.3% · OPM change 3 pp 88% evidence | 21.4/25 ROCE 28.4% · OPM 23% 100% evidence | 5.6/20 P/E 99.9× · PEG 2.65 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 23.9 + 21.4 + 5.6 + 10 = 60.9 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 11Ipca Laboratories LtdIPCALAB | 58.9/100Mixed-positive evidence78% evidence | BREAKING OUT | 22.2/35 Revenue 7.9% · PAT 51% · OPM change 1 pp 83% evidence | 15.3/25 ROCE 17% · OPM 20% 76% evidence | 11.0/20 P/E 37.6× · PEG — 50% evidence | 10.4/20 RS sector -2% · RS bench 15.1% · 1Y 15.8%7 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 15.3 + 11 + 10.4 = 58.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Marksans Pharma LtdMARKSANS | 58.3/100Mixed-positive evidence83% evidence | TURNING | 19.9/35 Revenue 12.5% · PAT 9.7% · OPM change 5 pp 88% evidence | 18.1/25 ROCE 18.8% · OPM 23% 100% evidence | 11.5/20 P/E 28× · PEG 1.41 65% evidence | 8.8/20 RS sector -18.1% · RS bench 30.6% · 1Y 13.4%11 of 11 weeks ahead 70% evidence |
| Exact sum: 19.9 + 18.1 + 11.5 + 8.8 = 58.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Wockhardt LtdWOCKPHARMA | 58.1/100Mixed-positive evidence71% evidence | LEADER | 22.6/35 Revenue 12% · PAT 100% · OPM change 14 pp 65% evidence | 9.0/25 ROCE 7.5% · OPM 23% 100% evidence | 8.7/20 P/E 112× · PEG — 15% evidence | 17.8/20 RS sector 10.5% · RS bench 29.2% · 1Y 16.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.6 + 9 + 8.7 + 17.8 = 58.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Accent Microcell LtdACCENTMIC | 58.1/100Mixed-positive evidence63% evidence | LEADER | 17.5/35 Revenue — · PAT — · OPM change -1 pp 26% evidence | 16.9/25 ROCE 24.9% · OPM 16% 95% evidence | 9.7/20 P/E 27.8× · PEG — 50% evidence | 14.0/20 RS sector 18.5% · RS bench 37.8% · 1Y 85.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 16.9 + 9.7 + 14 = 58.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Amrutanjan Health Care LtdAMRUTANJAN | 55.9/100Mixed-positive evidence77% evidence | ASLEEP | 20.9/35 Revenue 11.3% · PAT 11.8% · OPM change 4 pp 83% evidence | 17.0/25 ROCE 24.8% · OPM 17% 95% evidence | 14.2/20 P/E 23.1× · PEG — 50% evidence | 3.8/20 RS sector -24.6% · RS bench -18.4% · 1Y -24.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 20.9 + 17 + 14.2 + 3.8 = 55.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16RPG Life Sciences LtdRPGLIFE | 54.0/100Mixed-positive evidence93% evidence | LEADER | 11.8/35 Revenue 11.9% · PAT -34.1% · OPM change 1 pp 100% evidence | 17.3/25 ROCE 25.7% · OPM 22% 100% evidence | 10.2/20 P/E 39.2× · PEG 1.43 65% evidence | 14.7/20 RS sector 2.5% · RS bench 20.8% · 1Y 11.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 11.8 + 17.3 + 10.2 + 14.7 = 54 · Decision use: Price leads the evidence: RS versus the benchmark is 20.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 17Kilitch Drugs (India) LtdKILITCH | 53.7/100Mixed-positive evidence83% evidence | BREAKING OUT | 18.2/35 Revenue 19.8% · PAT 16% · OPM change 1 pp 83% evidence | 10.7/25 ROCE 14.4% · OPM 25% 95% evidence | 14.0/20 P/E 21.6× · PEG — 50% evidence | 10.8/20 RS sector -10.2% · RS bench 6.2% · 1Y -15%10 of 12 weeks ahead 100% evidence |
| Exact sum: 18.2 + 10.7 + 14 + 10.8 = 53.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Alkem Laboratories LtdALKEM | 53.6/100Mixed-positive evidence78% evidence | TURNING | 19.8/35 Revenue 13.5% · PAT 6.1% · OPM change 2 pp 83% evidence | 16.3/25 ROCE 21.2% · OPM 14% 76% evidence | 11.9/20 P/E 28.2× · PEG — 50% evidence | 5.6/20 RS sector -12.9% · RS bench 3% · 1Y 14.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 16.3 + 11.9 + 5.6 = 53.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19FDC LtdFDC | 52.2/100Mixed-positive evidence90% evidence | TURNING | 16.7/35 Revenue 3% · PAT 4.9% · OPM change 7 pp 88% evidence | 14.8/25 ROCE 16.7% · OPM 18% 100% evidence | 15.7/20 P/E 22.5× · PEG 0.93 100% evidence | 5.0/20 RS sector -25.2% · RS bench -0.4% · 1Y -16.2%6 of 10 weeks ahead 70% evidence |
| Exact sum: 16.7 + 14.8 + 15.7 + 5 = 52.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20ERIS Lifesciences LtdERIS | 51.6/100Mixed-positive evidence76% evidence | TURNING | 21.0/35 Revenue 9.6% · PAT 62.2% · OPM change -2 pp 95% evidence | 14.1/25 ROCE 14.1% · OPM 34% 76% evidence | 11.1/20 P/E 28.6× · PEG — 50% evidence | 5.4/20 RS sector -13.9% · RS bench -10.4% · 1Y -24.6%0 of 10 weeks ahead 70% evidence |
| Exact sum: 21 + 14.1 + 11.1 + 5.4 = 51.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Akums Drugs & Pharmaceuticals LtdAKUMS | 51.0/100Mixed-positive evidence71% evidence | LEADER | 13.9/35 Revenue 5.9% · PAT -25.3% · OPM change 4 pp 83% evidence | 10.3/25 ROCE 14.9% · OPM 13% 76% evidence | 9.6/20 P/E 38.6× · PEG — 15% evidence | 17.2/20 RS sector 11.1% · RS bench 29.9% · 1Y 24.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13.9 + 10.3 + 9.6 + 17.2 = 51 · Decision use: Price leads the evidence: RS versus the benchmark is 29.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 22J B Chemicals & Pharmaceuticals LtdJBCHEPHARM | 47.1/100Mixed-negative evidence96% evidence | 11.1/35 Revenue 5.9% · PAT 7.4% · OPM change -2 pp 88% evidence | 19.9/25 ROCE 25.4% · OPM 22% 100% evidence | 3.7/20 P/E 53.8× · PEG 2.34 100% evidence | 12.4/20 RS sector 2.9% · RS bench 23.5% · 1Y 41%6 of 10 weeks ahead 100% evidence | |
| Exact sum: 11.1 + 19.9 + 3.7 + 12.4 = 47.1 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 23Sun Pharmaceutical Industries LtdSUNPHARMA | 46.4/100Mixed-negative evidence100% evidence | BREAKING OUT | 17.8/35 Revenue 11.4% · PAT 16.5% · OPM change -2 pp 100% evidence | 16.3/25 ROCE 20.5% · OPM 29% 100% evidence | 4.0/20 P/E 37.8× · PEG 3.8 100% evidence | 8.3/20 RS sector -4.7% · RS bench 12.3% · 1Y 17.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 17.8 + 16.3 + 4 + 8.3 = 46.4 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 24Strides Pharma Science LtdSTAR | 46.1/100Mixed-negative evidence80% evidence | FADING | 16.2/35 Revenue 8.1% · PAT 79.1% · OPM change -1 pp 95% evidence | 12.1/25 ROCE 18.3% · OPM 18% 95% evidence | 11.3/20 P/E 16.3× · PEG — 15% evidence | 6.5/20 RS sector -9.2% · RS bench 6.6% · 1Y 12.9%9 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 12.1 + 11.3 + 6.5 = 46.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Torrent Pharmaceuticals LtdTORNTPHARM | 45.5/100Mixed-negative evidence100% evidence | BREAKING OUT | 16.7/35 Revenue 32.9% · PAT 7.7% · OPM change 2 pp 100% evidence | 13.2/25 ROCE 15.2% · OPM 34% 100% evidence | 0.9/20 P/E 87.3× · PEG 5.11 100% evidence | 14.7/20 RS sector 5.4% · RS bench 23.6% · 1Y 41.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 16.7 + 13.2 + 0.9 + 14.7 = 45.5 · Decision use: Price leads the evidence: RS versus the benchmark is 23.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 26Biocon LtdBIOCON | 42.5/100Mixed-negative evidence96% evidence | BREAKING OUT | 12.1/35 Revenue 10.9% · PAT -74.2% · OPM change -1 pp 88% evidence | 10.8/25 ROCE 3.6% · OPM 23% 100% evidence | 9.9/20 P/E 178× · PEG 0.82 100% evidence | 9.7/20 RS sector -7.4% · RS bench 9% · 1Y 8%8 of 12 weeks ahead 100% evidence |
| Exact sum: 12.1 + 10.8 + 9.9 + 9.7 = 42.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Mankind Pharma LtdMANKIND | 42.4/100Mixed-negative evidence100% evidence | BREAKING OUT | 17.1/35 Revenue 14.2% · PAT 8% · OPM change 2 pp 100% evidence | 12.6/25 ROCE 13.5% · OPM 26% 100% evidence | 4.9/20 P/E 47.8× · PEG 2.81 100% evidence | 7.8/20 RS sector -11.1% · RS bench 4.9% · 1Y -5.1%10 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 12.6 + 4.9 + 7.8 = 42.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Gufic BioSciences LtdGUFICBIO | 41.9/100Mixed-negative evidence90% evidence | TURNING | 19.6/35 Revenue 15.1% · PAT -8.6% · OPM change 6 pp 88% evidence | 12.6/25 ROCE 12.3% · OPM 19% 100% evidence | 2.0/20 P/E 60.9× · PEG 4.78 100% evidence | 7.7/20 RS sector -18.5% · RS bench 14.8% · 1Y 0.7%9 of 11 weeks ahead 70% evidence |
| Exact sum: 19.6 + 12.6 + 2 + 7.7 = 41.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Aurobindo Pharma LtdAUROPHARMA | 41.1/100Mixed-negative evidence96% evidence | LEADER | 11.5/35 Revenue 6.1% · PAT 0.6% · OPM change -1 pp 88% evidence | 13.3/25 ROCE 12.8% · OPM 20% 100% evidence | 4.1/20 P/E 25.9× · PEG 2.67 100% evidence | 12.2/20 RS sector 4.4% · RS bench 22.3% · 1Y 40.7%11 of 12 weeks ahead 100% evidence |
| Exact sum: 11.5 + 13.3 + 4.1 + 12.2 = 41.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30Natco Pharma LtdNATCOPHARM | 39.8/100Mixed-negative evidence96% evidence | ASLEEP | 5.1/35 Revenue -8% · PAT -24.6% · OPM change -28 pp 88% evidence | 12.9/25 ROCE 17.1% · OPM 17% 100% evidence | 19.1/20 P/E 11.6× · PEG 0.76 100% evidence | 2.7/20 RS sector -17.3% · RS bench -2.6% · 1Y -5.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 5.1 + 12.9 + 19.1 + 2.7 = 39.8 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 31Lincoln Pharmaceuticals LtdLINCOLN | 39.4/100Mixed-negative evidence83% evidence | ASLEEP | 11.6/35 Revenue 7.5% · PAT 7.2% · OPM change -3 pp 83% evidence | 14.2/25 ROCE 16.3% · OPM 13% 95% evidence | 9.8/20 P/E 13.2× · PEG — 50% evidence | 3.8/20 RS sector -14.7% · RS bench 0.2% · 1Y 6.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 11.6 + 14.2 + 9.8 + 3.8 = 39.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 32Zim Laboratories LtdZIMLAB | 39.1/100Mixed-negative evidence76% evidence | LEADER | 6.0/35 Revenue -1.2% · PAT -51.9% · OPM change -6.6 pp 83% evidence | 6.1/25 ROCE 4.8% · OPM 6.8% 95% evidence | 8.7/20 P/E 139× · PEG — 15% evidence | 18.3/20 RS sector 16.5% · RS bench 35.4% · 1Y 0%12 of 12 weeks ahead 100% evidence |
| Exact sum: 6 + 6.1 + 8.7 + 18.3 = 39.1 · Decision use: Price leads the evidence: RS versus the benchmark is 35.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 33Suven Life Sciences LtdSUVEN | 38.4/100Thin evidence · provisional58% evidence | TURNING | 18.2/35 Revenue 14.3% · PAT -72% · OPM change -350 pp 65% evidence | 2.1/25 ROCE -76.9% · OPM — 84% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.1/20 RS sector -30.9% · RS bench 46.4% · 1Y 9.2%11 of 11 weeks ahead 70% evidence |
| Exact sum: 18.2 + 2.1 + 10 + 8.1 = 38.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 34Indoco Remedies LtdINDOCO | 38.2/100Thin evidence · provisional58% evidence | TURNING | 20.4/35 Revenue 11.9% · PAT 100% · OPM change 5 pp 71% evidence | 4.3/25 ROCE 0.9% · OPM 9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.5/20 RS sector -32.2% · RS bench -9.2% · 1Y -30.8%6 of 10 weeks ahead 70% evidence |
| Exact sum: 20.4 + 4.3 + 10 + 3.5 = 38.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 35Alembic Pharmaceuticals LtdAPLLTD | 38.1/100Mixed-negative evidence90% evidence | TURNING | 14.4/35 Revenue 10.1% · PAT 15.3% · OPM change -3 pp 88% evidence | 6.9/25 ROCE 12.6% · OPM 12% 100% evidence | 12.3/20 P/E 21.4× · PEG 1.74 100% evidence | 4.5/20 RS sector -24.1% · RS bench -4.7% · 1Y -20.1%2 of 11 weeks ahead 70% evidence |
| Exact sum: 14.4 + 6.9 + 12.3 + 4.5 = 38.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 36Bajaj Healthcare LtdBAJAJHCARE | 36.0/100Mixed-negative evidence87% evidence | FADING | 9.9/35 Revenue 12.3% · PAT -59.1% · OPM change 1 pp 95% evidence | 10.4/25 ROCE 11.5% · OPM 17% 95% evidence | 10.8/20 P/E 20.1× · PEG — 50% evidence | 4.9/20 RS sector -26.4% · RS bench -12.1% · 1Y -34.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 9.9 + 10.4 + 10.8 + 4.9 = 36 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 37Cipla LtdCIPLA | 35.9/100Mixed-negative evidence100% evidence | BREAKING OUT | 4.9/35 Revenue 1.8% · PAT -37.7% · OPM change -9 pp 100% evidence | 11.3/25 ROCE 15.5% · OPM 17% 100% evidence | 12.1/20 P/E 33.2× · PEG 1.25 100% evidence | 7.6/20 RS sector -14.5% · RS bench 1.3% · 1Y -3.9%7 of 12 weeks ahead 100% evidence |
| Exact sum: 4.9 + 11.3 + 12.1 + 7.6 = 35.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 38Bharat Parenterals Ltd541096 | 34.7/100Thin evidence · provisional55% evidence | TURNING | 13.5/35 Revenue 1.5% · PAT 37.5% · OPM change -2.7 pp 62% evidence | 3.5/25 ROCE -1.8% · OPM -0.5% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 7.7/20 RS sector -20.9% · RS bench 17.8% · 1Y -5.2%11 of 11 weeks ahead 70% evidence |
| Exact sum: 13.5 + 3.5 + 10 + 7.7 = 34.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 39Dr Reddys Laboratories LtdDRREDDY | 29.9/100Adverse evidence100% evidence | ASLEEP | 4.1/35 Revenue -0.9% · PAT -44.6% · OPM change -14 pp 100% evidence | 10.7/25 ROCE 13% · OPM 11% 100% evidence | 13.5/20 P/E 29.7× · PEG 1.15 100% evidence | 1.6/20 RS sector -24.3% · RS bench -10.6% · 1Y -10.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 4.1 + 10.7 + 13.5 + 1.6 = 29.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 40Influx Healthtech Ltdthis pageINFLUX | 65.1/100Thin evidence · provisional50% evidence | BREAKING OUT | 19.1/35 Revenue — · PAT — · OPM change -1 pp 26% evidence | 20.3/25 ROCE 40% · OPM 19% 95% evidence | 10.0/20 P/E 33.4× · PEG — 15% evidence | 15.7/20 RS sector 12.1% · RS bench 31.1% · 1Y 90.7%9 of 12 weeks ahead 70% evidence |
| Exact sum: 19.1 + 20.3 + 10 + 15.7 = 65.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 41Syncom Healthcare LtdSYNCOM | 50.5/100Thin evidence · provisional31% evidence | 17.2/35 Revenue -69.4% · PAT 63.5% · OPM change — 16% evidence | 6.9/25 ROCE -20.2% · OPM -225.7% 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 16.4/20 RS sector 29.1% · RS bench 45.7% · 1Y —9 of 12 weeks ahead to 2021-06-30 70% evidence | |
| Exact sum: 17.2 + 6.9 + 10 + 16.4 = 50.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 42Fredun Pharmaceuticals Ltd539730 | 47.8/100Thin evidence · provisional49% evidence | ASLEEP | 19.1/35 Revenue — · PAT — · OPM change 4 pp 20% evidence | 14.7/25 ROCE 21.3% · OPM 14% 76% evidence | 9.2/20 P/E 50× · PEG — 15% evidence | 4.8/20 RS sector -45.5% · RS bench 59.4% · 1Y 6.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 14.7 + 9.2 + 4.8 = 47.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 43Sai Parenterals LtdSAIPARENT | 39.1/100Thin evidence · provisional33% evidence | TURNING | 15.2/35 Revenue — · PAT — · OPM change — 16% evidence | 5.3/25 ROCE 6% · OPM 13% 95% evidence | 8.6/20 P/E 170× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —3 of 3 weeks ahead 0% evidence |
| Exact sum: 15.2 + 5.3 + 8.6 + 10 = 39.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Influx Healthtech Ltd's share price today?
Influx Healthtech Ltd trades at ₹296, +91.0% over the past year. The company is valued at ₹686 Cr. The stock sits at 96% of its 52-week range of ₹169–₹301, +26.3% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 56 weeks in. — as of 31 July 2026.
What were Influx Healthtech Ltd's latest quarterly results?
Influx Healthtech Ltd reported revenue of ₹80.0 Cr and net profit of ₹11.0 Cr for the Mar 26 quarter. Revenue rose 40.4% and profit rose 37.5% year on year. Earnings per share were ₹4.56. The operating margin was 19.0%, 1.0 pp lower than a year earlier. — as of 31 July 2026.
What is Influx Healthtech Ltd's revenue?
Influx Healthtech Ltd reported revenue of ₹80.0 Cr in the Mar 26 quarter, +40.4% year on year. For the full FY26 fiscal year, revenue was ₹147 Cr (+40.0%). — as of 31 July 2026.
What is Influx Healthtech Ltd's profit?
Influx Healthtech Ltd earned ₹11.0 Cr of net profit in the Mar 26 quarter, +37.5% year on year — the 2nd straight quarter of growth. Full-year FY26 profit was ₹21.0 Cr. The operating margin ran 19.0% in the latest quarter. — as of 31 July 2026.
What is Influx Healthtech Ltd's market cap?
Influx Healthtech Ltd's market capitalisation is ₹686 Cr at a share price of ₹296. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Influx Healthtech Ltd's P/E ratio?
Influx Healthtech Ltd trades at a P/E of 33.4×, at the 97th percentile of its own 1-year range, against a long-run median of 25.8×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Influx Healthtech Ltd pay a dividend?
No — Influx Healthtech Ltd has recorded a dividend payout of 0% of profit in each of its last 5 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 31 July 2026.
Is Influx Healthtech Ltd overvalued?
On its own history, Influx Healthtech Ltd looks expensive against its own history: its P/E of 33.4× sits at the 97th percentile of its 1-year range (long-run median 25.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 31 July 2026.
Is Influx Healthtech Ltd growing?
Yes — Influx Healthtech Ltd is growing: latest-quarter revenue +40.4% year on year, profit +37.5%, and the margin −1.0 pp at 19.0%. The earnings engine currently reads: improving — as of 31 July 2026.
How is Influx Healthtech Ltd performing?
Influx Healthtech Ltd is in a confirmed uptrend, 56 weeks in. Its latest quarter's revenue rose 40.4% and profit rose 37.5% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 5 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
Is Influx Healthtech Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 56 of stage 2), trading +26.3% versus its 200-day average and at 96% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Influx Healthtech Ltd beating the market?
On recent form, yes — Influx Healthtech Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 5 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.1 years the stock moved +120% against the NIFTY 500's +0% — ahead of the index over the full window. — as of 31 July 2026.
Will Influx Healthtech Ltd's share price go up?
This page publishes no price forecast for Influx Healthtech Ltd. What it measures instead: the share price is ₹296, the price is in a confirmed uptrend 56 weeks in. Its P/E of 33.4× sits at the 97th percentile of its own 1-year range. — as of 31 July 2026.
Who owns Influx Healthtech Ltd?
Promoters hold 73.5% of Influx Healthtech Ltd, foreign institutions 0.2%, domestic institutions 5.7% and the public 20.7% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 31 July 2026.
Does Influx Healthtech Ltd have too much debt?
No — Influx Healthtech Ltd's debt-to-equity is 0.00. FY26 borrowings were ₹0.0 Cr against equity of ₹101 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Influx Healthtech Ltd's capex?
Influx Healthtech Ltd spent ₹34.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹16.0 Cr, with ₹3.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Influx Healthtech Ltd's cash flow?
Influx Healthtech Ltd generated ₹4.0 Cr of operating cash flow in FY26 and ₹−12.0 Cr of free cash flow after ₹16.0 Cr of capital spending. Reported profit that year was ₹21.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Influx Healthtech Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 44% of Influx Healthtech Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹4.0 Cr against reported profit of ₹21.0 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 31 July 2026.
How financially safe is Influx Healthtech Ltd?
On the balance sheet, the Z-score reads 15.04 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 31 July 2026.
Where is Influx Healthtech Ltd in its business cycle?
Influx Healthtech Ltd's FY26 operating margin was 20.0%, against a 5-year band of 11.0%–20.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 19.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Influx Healthtech Ltd story?
The sharpest disagreement: profits are rising, but only 44% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Influx Healthtech Ltd a stock worth studying right now?
This is not investment advice. The machine read: Influx Healthtech Ltd's price has outrun its earnings. +91.0% in a year against EPS +20.4% — the market is paying now for delivery later. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.